{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:56:20Z","timestamp":1790610980120,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-026-03300-2","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:12:17Z","timestamp":1790608337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous infusion therapy after deep brain stimulation in Parkinson\u2019s disease: indications, outcomes, and patient selection"],"prefix":"10.1007","author":[{"given":"Mario","family":"Hero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli\u0161a","family":"Papi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Grozdani\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimira","family":"Vuleti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"3300_CR1","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther 12:1937\u20131958. https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Ther"},{"key":"3300_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000049597","volume":"105","author":"A Ali","year":"2026","unstructured":"Ali A, Cheema WA, Shamoon M et al (2026) Continuous subcutaneous levodopa and foslevodopa infusion therapy for motor symptoms of Parkinson disease: a systematic review of observational studies. Medicine (Baltimore) 105:e49597. https:\/\/doi.org\/10.1097\/MD.0000000000049597","journal-title":"Medicine (Baltimore)"},{"key":"3300_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Parkinsonism Relat Disord"},{"key":"3300_CR4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1080\/03007995.2018.1502165","volume":"34","author":"A Antonini","year":"2018","unstructured":"Antonini A, Stoessl AJ, Kleinman LS et al (2018) Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson\u2019s disease: a multi-country Delphi-panel approach. Curr Med Res Opin 34:2063\u20132073. https:\/\/doi.org\/10.1080\/03007995.2018.1502165","journal-title":"Curr Med Res Opin"},{"key":"3300_CR5","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00702-023-02693-8","volume":"130","author":"A Antonini","year":"2023","unstructured":"Antonini A, D\u2019Onofrio V, Guerra A (2023) Current and novel infusion therapies for patients with Parkinson\u2019s disease. J Neural Transm (Vienna) 130:1349\u20131358. https:\/\/doi.org\/10.1007\/s00702-023-02693-8","journal-title":"J Neural Transm (Vienna)"},{"key":"3300_CR6","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","volume":"130","author":"M Auffret","year":"2023","unstructured":"Auffret M, Weiss D, Stocchi F, V\u00e9rin M, Jost WH (2023) Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty. J Neural Transm (Vienna) 130:1411\u20131432. https:\/\/doi.org\/10.1007\/s00702-023-02668-9","journal-title":"J Neural Transm (Vienna)"},{"key":"3300_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2026-001577","volume":"8","author":"M Auffret","year":"2026","unstructured":"Auffret M, Nowak E, V\u00e9rin M, Kerbrat S (2026) Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson\u2019s disease: insights from the French National Healthcare Data System (2015\u20132021). BMJ Neurol Open 8:e001577. https:\/\/doi.org\/10.1136\/bmjno-2026-001577","journal-title":"BMJ Neurol Open"},{"key":"3300_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/jnnp-2013-306907","volume":"85","author":"I Aviles-Olmos","year":"2014","unstructured":"Aviles-Olmos I, Kefalopoulou Z, Tripoliti E et al (2014) Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson\u2019s disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry 85:1419\u20131425. https:\/\/doi.org\/10.1136\/jnnp-2013-306907","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3300_CR9","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/mds.23800","volume":"26","author":"JF Baizabal Carvallo","year":"2011","unstructured":"Baizabal Carvallo JF, Simpson R, Jankovic J (2011) Diagnosis and treatment of complications related to deep brain stimulation hardware. Mov Disord 26:1398\u20131406. https:\/\/doi.org\/10.1002\/mds.23800","journal-title":"Mov Disord"},{"key":"3300_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/ene.12614","volume":"23","author":"M Bang Henriksen","year":"2016","unstructured":"Bang Henriksen M, Johnsen EL, Sunde N et al (2016) Surviving 10 years with deep brain stimulation for Parkinson\u2019s disease: a follow-up of 79 patients. Eur J Neurol 23:53\u201361. https:\/\/doi.org\/10.1111\/ene.12614","journal-title":"Eur J Neurol"},{"key":"3300_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.14802\/jmd.19051","volume":"13","author":"JMP Bautista","year":"2020","unstructured":"Bautista JMP, Oyama G, Nuermaimaiti M et al (2020) Rescue levodopa\/carbidopa intestinal gel for secondary deep brain stimulation failure. J Mov Disord 13:57\u201361. https:\/\/doi.org\/10.14802\/jmd.19051","journal-title":"J Mov Disord"},{"key":"3300_CR12","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/mdc3.13228","volume":"8","author":"I Boura","year":"2021","unstructured":"Boura I, Haliasos N, Giannopoulou IA, Karabetsos D, Spanaki C (2021) Combining device-aided therapies in Parkinson\u2019s disease: a case series and a literature review. Mov Disord Clin Pract 8:750\u2013757. https:\/\/doi.org\/10.1002\/mdc3.13228","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/jamaneurol.2025.2781","volume":"82","author":"HM Bronte-Stewart","year":"2025","unstructured":"Bronte-Stewart HM, Beudel M, Ostrem JL et al (2025) Long-term personalized adaptive deep brain stimulation in Parkinson disease: a nonrandomized clinical trial. JAMA Neurol 82:1171\u20131180. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2781","journal-title":"JAMA Neurol"},{"key":"3300_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00702-017-1698-7","volume":"124","author":"C Buhmann","year":"2017","unstructured":"Buhmann C, Hilker R, Lingor P, Schrader C, Schwarz J, Wolz M, Reichmann H (2017) Levodopa\/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy. J Neural Transm (Vienna) 124:1005\u20131013. https:\/\/doi.org\/10.1007\/s00702-017-1698-7","journal-title":"J Neural Transm (Vienna)"},{"key":"3300_CR15","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/archneurol.2011.182","volume":"68","author":"A Castrioto","year":"2011","unstructured":"Castrioto A, Lozano AM, Poon YY et al (2011) Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 68:1550\u20131556. https:\/\/doi.org\/10.1001\/archneurol.2011.182","journal-title":"Arch Neurol"},{"key":"3300_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-026-01453-1","author":"F Colucci","year":"2026","unstructured":"Colucci F, Kaymak A, Antenucci P et al (2026) STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson\u2019s disease. NPJ Parkinsons Dis. https:\/\/doi.org\/10.1038\/s41531-026-01453-1","journal-title":"NPJ Parkinsons Dis"},{"key":"3300_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mds.27626","volume":"34","author":"HS Dafsari","year":"2019","unstructured":"Dafsari HS, Martinez-Martin P, Rizos A et al (2019) EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson\u2019s disease. Mov Disord 34:353\u2013365. https:\/\/doi.org\/10.1002\/mds.27626","journal-title":"Mov Disord"},{"key":"3300_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2026.108302","volume":"147","author":"D De Monte","year":"2026","unstructured":"De Monte D, Ermanis G, Bernardini A et al (2026) Continuous subcutaneous levodopa infusion in advanced Parkinson\u2019s disease patients with subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord 147:108302. https:\/\/doi.org\/10.1016\/j.parkreldis.2026.108302","journal-title":"Parkinsonism Relat Disord"},{"key":"3300_CR19","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/acn3.70225","volume":"13","author":"C Del Regno","year":"2026","unstructured":"Del Regno C, Ermanis G, Lettieri C et al (2026) RAB39B related parkinsonism in an Italian family: a unique use of advanced therapies. Ann Clin Transl Neurol 13:204\u2013208. https:\/\/doi.org\/10.1002\/acn3.70225","journal-title":"Ann Clin Transl Neurol"},{"key":"3300_CR20","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J et al (2022) European Academy of Neurology\/Movement Disorder Society-European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Mov Disord 37:1360\u20131374. https:\/\/doi.org\/10.1002\/mds.29066","journal-title":"Mov Disord"},{"key":"3300_CR21","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/acn3.50889","volume":"6","author":"A Elkouzi","year":"2019","unstructured":"Elkouzi A, Ramirez-Zamora A, Zeilman P et al (2019) Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson\u2019s disease patients with suboptimal response to deep brain stimulation. Ann Clin Transl Neurol 6:1989\u20131995. https:\/\/doi.org\/10.1002\/acn3.50889","journal-title":"Ann Clin Transl Neurol"},{"key":"3300_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1212\/WNL.0b013e3182477ec0","volume":"78","author":"AJ Espay","year":"2012","unstructured":"Espay AJ, Fasano A, van Nuenen BF et al (2012) On state freezing of gait in Parkinson disease: a paradoxical levodopa-induced complication. Neurology 78:454\u2013457. https:\/\/doi.org\/10.1212\/WNL.0b013e3182477ec0","journal-title":"Neurology"},{"key":"3300_CR23","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/mds.23583","volume":"26","author":"A Fasano","year":"2011","unstructured":"Fasano A, Herzog J, Seifert E et al (2011) Modulation of gait coordination by subthalamic stimulation improves freezing of gait. Mov Disord 26:844\u2013851. https:\/\/doi.org\/10.1002\/mds.23583","journal-title":"Mov Disord"},{"key":"3300_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nrneurol.2014.252","volume":"11","author":"A Fasano","year":"2015","unstructured":"Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR (2015) Axial disability and deep brain stimulation in patients with Parkinson disease. Nat Rev Neurol 11:98\u2013110. https:\/\/doi.org\/10.1038\/nrneurol.2014.252","journal-title":"Nat Rev Neurol"},{"key":"3300_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mds.26123","volume":"30","author":"HH Fernandez","year":"2015","unstructured":"Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease: final 12-month, open-label results. Mov Disord 30:500\u2013509. https:\/\/doi.org\/10.1002\/mds.26123","journal-title":"Mov Disord"},{"key":"3300_CR26","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/mdc3.13338","volume":"8","author":"G Fern\u00e1ndez-Pajar\u00edn","year":"2021","unstructured":"Fern\u00e1ndez-Pajar\u00edn G, Sesar \u00c1, Ares B et al (2021) Continuous subcutaneous apomorphine infusion before subthalamic deep brain stimulation: a prospective, comparative study in 20 patients. Mov Disord Clin Pract 8:1216\u20131224. https:\/\/doi.org\/10.1002\/mdc3.13338","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR27","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1212\/01.wnl.0000310416.90757.85","volume":"70","author":"MU Ferraye","year":"2008","unstructured":"Ferraye MU, Deb\u00fb B, Fraix V et al (2008) Effects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson disease. Neurology 70:1431\u20131437. https:\/\/doi.org\/10.1212\/01.wnl.0000310416.90757.85","journal-title":"Neurology"},{"key":"3300_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2025.107950","volume":"138","author":"M Garon","year":"2025","unstructured":"Garon M, Scharfenort M, Antonini A, Odin P, Ljung H (2025) Cognitive outcomes of infusion therapies in Parkinson\u2019s disease: a comprehensive systematic review. Parkinsonism Relat Disord 138:107950. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107950","journal-title":"Parkinsonism Relat Disord"},{"key":"3300_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5603\/pjnns.102858","volume":"59","author":"D Georgiev","year":"2025","unstructured":"Georgiev D, Tro\u0161t M (2025) Long-term effect and reasons for switching and combining device-aided therapies in Parkinson\u2019s disease. Neurol Neurochir Pol 59:111\u2013126. https:\/\/doi.org\/10.5603\/pjnns.102858","journal-title":"Neurol Neurochir Pol"},{"key":"3300_CR30","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/brainsci12030343","volume":"12","author":"D Georgiev","year":"2022","unstructured":"Georgiev D, Delali\u0107 S, Zupan\u010di\u010d Kri\u017enar N et al (2022) Switching and combining device-aided therapies in advanced Parkinson\u2019s disease: a double centre retrospective study. Brain Sci 12:343. https:\/\/doi.org\/10.3390\/brainsci12030343","journal-title":"Brain Sci"},{"key":"3300_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00415-009-0076-2","volume":"256","author":"H Gervais-Bernard","year":"2009","unstructured":"Gervais-Bernard H, Xie-Brustolin J, Mertens P et al (2009) Bilateral subthalamic nucleus stimulation in advanced Parkinson\u2019s disease: five year follow-up. J Neurol 256:225\u2013233. https:\/\/doi.org\/10.1007\/s00415-009-0076-2","journal-title":"J Neurol"},{"key":"3300_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1627264","author":"B Gonz\u00e1lez-Herrero","year":"2020","unstructured":"Gonz\u00e1lez-Herrero B, Jauma-Classen S, G\u00f3mez-Llopico R, Plans G, Calopa M (2020) Intestinal levodopa\/carbidopa infusion as a therapeutic option for unresponsive freezing of gait after deep brain stimulation in Parkinson\u2019s disease. Parkinsons Dis. https:\/\/doi.org\/10.1155\/2020\/1627264","journal-title":"Parkinsons Dis"},{"key":"3300_CR33","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/mdc3.70557","volume":"13","author":"J Hartig","year":"2026","unstructured":"Hartig J, Sitzmann L, Hartenstein D et al (2026) Continuous subcutaneous versus intestinal levodopa infusion for Parkinson\u2019s disease: a real-world, monocentric, observational study and critical review. Mov Disord Clin Pract 13:1662\u20131672. https:\/\/doi.org\/10.1002\/mdc3.70557","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR34","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1007\/s12325-026-03579-3","volume":"43","author":"T Henriksen","year":"2026","unstructured":"Henriksen T, Mart\u00ednez-Castrillo JC, Huisman MHB et al (2026) Foslevodopa\/foscarbidopa subcutaneous infusion safety and efficacy in patients with and without prior deep brain stimulation. Adv Ther 43:2736\u20132751. https:\/\/doi.org\/10.1007\/s12325-026-03579-3","journal-title":"Adv Ther"},{"key":"3300_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70773","author":"M Hero","year":"2026","unstructured":"Hero M, Grozdani\u0107 N, Andri\u0107 RB, Papi\u0107 E, Perkovi\u0107 O, Vuleti\u0107 V (2026) Continuous subcutaneous foslevodopa\/foscarbidopa in advanced Parkinson\u2019s disease. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70773","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR36","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/mds.30026","volume":"39","author":"K Hines","year":"2024","unstructured":"Hines K, Noecker AM, Frankemolle-Gilbert AM et al (2024) Prospective connectomic-based deep brain stimulation programming for Parkinson\u2019s disease. Mov Disord 39:2249\u20132258. https:\/\/doi.org\/10.1002\/mds.30026","journal-title":"Mov Disord"},{"key":"3300_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuroimage.2014.12.002","volume":"107","author":"A Horn","year":"2015","unstructured":"Horn A, K\u00fchn AA (2015) Lead-DBS: a toolbox for deep brain stimulation electrode localizations and visualizations. NeuroImage 107:127\u2013135. https:\/\/doi.org\/10.1016\/j.neuroimage.2014.12.002","journal-title":"NeuroImage"},{"key":"3300_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.neuroimage.2018.08.068","volume":"184","author":"A Horn","year":"2019","unstructured":"Horn A, Li N, Dembek TA et al (2019) Lead-DBS v2: towards a comprehensive pipeline for deep brain stimulation imaging. Neuroimage 184:293\u2013316. https:\/\/doi.org\/10.1016\/j.neuroimage.2018.08.068","journal-title":"Neuroimage"},{"key":"3300_CR39","unstructured":"Howick J, Chalmers I, Glasziou P et al (2011) The 2011 Oxford CEBM levels of evidence (Introductory Document). Oxford centre for evidence-based medicine, Oxford. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed 6 Sept 2026"},{"key":"3300_CR40","doi-asserted-by":"publisher","unstructured":"Jost WH (2025) Dichotomous thinking in Parkinson therapy? J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-025-03089-6","DOI":"10.1007\/s00702-025-03089-6"},{"key":"3300_CR41","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","volume":"17","author":"R Katzenschlager","year":"2018","unstructured":"Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749\u2013759. https:\/\/doi.org\/10.1016\/S1474-4422(18)30239-4","journal-title":"Lancet Neurol"},{"key":"3300_CR42","doi-asserted-by":"publisher","first-page":"192","DOI":"10.14802\/jmd.19022","volume":"12","author":"TE Kimber","year":"2019","unstructured":"Kimber TE, Zhuang Y, Thompson PD (2019) Benefits of levodopa-carbidopa intestinal gel infusion in patients with Parkinson\u2019s disease experiencing gait dysfunction following subthalamic deep brain stimulation. J Mov Disord 12:192\u2013194. https:\/\/doi.org\/10.14802\/jmd.19022","journal-title":"J Mov Disord"},{"key":"3300_CR43","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/mdc3.14352","volume":"12","author":"P Klocke","year":"2025","unstructured":"Klocke P, Loeffler MA, Cebi I et al (2025) Localization matters: impacts of PEG-J localization in intestinal levodopa therapy for Parkinson\u2019s disease. Mov Disord Clin Pract 12:614\u2013625. https:\/\/doi.org\/10.1002\/mdc3.14352","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR44","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1002\/mds.23833","volume":"26","author":"F Klostermann","year":"2011","unstructured":"Klostermann F, Jugel C, Marzinzik F (2011) Jejunal levodopa infusion in long-term DBS patients with Parkinson\u2019s disease. Mov Disord 26:2298\u20132299. https:\/\/doi.org\/10.1002\/mds.23833","journal-title":"Mov Disord"},{"key":"3300_CR45","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fneur.2019.00410","volume":"10","author":"T Koeglsperger","year":"2019","unstructured":"Koeglsperger T, Palleis C, Hell F, Mehrkens JH, B\u00f6tzel K (2019) Deep brain stimulation programming for movement disorders: current concepts and evidence-based strategies. Front Neurol 10:410. https:\/\/doi.org\/10.3389\/fneur.2019.00410","journal-title":"Front Neurol"},{"key":"3300_CR46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00702-025-02911-5","volume":"133","author":"T Koeglsperger","year":"2026","unstructured":"Koeglsperger T, Berberovic E, Dresel C et al (2026) Real-world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations. J Neural Transm (Vienna) 133:347\u2013359. https:\/\/doi.org\/10.1007\/s00702-025-02911-5","journal-title":"J Neural Transm (Vienna)"},{"key":"3300_CR47","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa035275","volume":"349","author":"P Krack","year":"2003","unstructured":"Krack P, Batir A, Van Blercom N et al (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson\u2019s disease. N Engl J Med 349:1925\u20131934. https:\/\/doi.org\/10.1056\/NEJMoa035275","journal-title":"N Engl J Med"},{"key":"3300_CR48","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/mds.27211","volume":"33","author":"N Kumar","year":"2018","unstructured":"Kumar N, Murgai A, Naranian T, Jog M, Fasano A (2018) Levodopa-carbidopa intestinal gel therapy after deep brain stimulation. Mov Disord 33:334\u2013335. https:\/\/doi.org\/10.1002\/mds.27211","journal-title":"Mov Disord"},{"key":"3300_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin P, Foltynie T (2019) Long-term outcomes of deep brain stimulation in Parkinson disease. Nat Rev Neurol 15:234\u2013242. https:\/\/doi.org\/10.1038\/s41582-019-0145-9","journal-title":"Nat Rev Neurol"},{"key":"3300_CR50","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/mdc3.13277","volume":"8","author":"M Marano","year":"2021","unstructured":"Marano M, Fasano A (2021) Subthalamic nucleus deep brain stimulation as rescue therapy for levodopa carbidopa intestinal gel-associated biphasic-like dyskinesias. Mov Disord Clin Pract 8:1155\u20131156. https:\/\/doi.org\/10.1002\/mdc3.13277","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/ene.12846","volume":"23","author":"A Merola","year":"2016","unstructured":"Merola A, Romagnolo A, Zibetti M et al (2016) Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: a long-term prospective assessment. Eur J Neurol 23:501\u2013509. https:\/\/doi.org\/10.1111\/ene.12846","journal-title":"Eur J Neurol"},{"key":"3300_CR52","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00702-023-02656-z","volume":"130","author":"HR Moes","year":"2023","unstructured":"Moes HR, Henriksen T, S\u0142awek J, Phokaewvarangkul O, Buskens E, van Laar T (2023) Tools and criteria to select patients with advanced Parkinson\u2019s disease for device-aided therapies: a narrative review. J Neural Transm (Vienna) 130:1359\u20131377. https:\/\/doi.org\/10.1007\/s00702-023-02656-z","journal-title":"J Neural Transm (Vienna)"},{"key":"3300_CR53","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00702-024-02783-1","volume":"131","author":"HR Moes","year":"2024","unstructured":"Moes HR, Dafsari HS, Jost WH et al (2024) Grasping the big picture: impact analysis of screening tools for timely referral for device-aided therapies. J Neural Transm (Vienna) 131:1295\u20131305. https:\/\/doi.org\/10.1007\/s00702-024-02783-1","journal-title":"J Neural Transm (Vienna)"},{"key":"3300_CR54","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/archneur.63.9.1266","volume":"63","author":"E Moro","year":"2006","unstructured":"Moro E, Poon YY, Lozano AM, Saint-Cyr JA, Lang AE (2006) Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol 63:1266\u20131272. https:\/\/doi.org\/10.1001\/archneur.63.9.1266","journal-title":"Arch Neurol"},{"key":"3300_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1017\/cjn.2018.366","volume":"46","author":"N Nathoo","year":"2019","unstructured":"Nathoo N, Sankar T, Suchowersky O, Ba F (2019) Deep brain stimulation as a rescue when duodenal levodopa infusion fails. Can J Neurol Sci 46:130\u2013131. https:\/\/doi.org\/10.1017\/cjn.2018.366","journal-title":"Can J Neurol Sci"},{"key":"3300_CR56","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1474-4422(15)00041-1","volume":"14","author":"J Nonnekes","year":"2015","unstructured":"Nonnekes J, Snijders AH, Nutt JG, Deuschl G, Giladi N, Bloem BR (2015) Freezing of gait: a practical approach to management. Lancet Neurol 14:768\u2013778. https:\/\/doi.org\/10.1016\/S1474-4422(15)00041-1","journal-title":"Lancet Neurol"},{"key":"3300_CR57","doi-asserted-by":"publisher","first-page":"239","DOI":"10.14802\/jmd.20090","volume":"14","author":"Y Noui","year":"2021","unstructured":"Noui Y, Silverdale MA, Evans J, Partington-Smith L, Kobylecki C (2021) Parkinson\u2019s kinetigraph in the selection of levodopa-carbidopa intestinal gel for motor fluctuations refractory to deep brain stimulation. J Mov Disord 14:239\u2013241. https:\/\/doi.org\/10.14802\/jmd.20090","journal-title":"J Mov Disord"},{"key":"3300_CR58","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(11)70143-0","volume":"10","author":"JG Nutt","year":"2011","unstructured":"Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A (2011) Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol 10:734\u2013744. https:\/\/doi.org\/10.1016\/S1474-4422(11)70143-0","journal-title":"Lancet Neurol"},{"key":"3300_CR59","doi-asserted-by":"publisher","first-page":"175628642211080","DOI":"10.1177\/17562864221108018","volume":"15","author":"D Nyholm","year":"2022","unstructured":"Nyholm D, Jost WH (2022) Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-world experience and practical guidance. Ther Adv Neurol Disord 15:17562864221108018. https:\/\/doi.org\/10.1177\/17562864221108018","journal-title":"Ther Adv Neurol Disord"},{"key":"3300_CR60","unstructured":"OCEBM Levels of Evidence Working Group (2011) The Oxford levels of evidence 2, version 2.1. oxford centre for evidence-based medicine, Oxford. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed 6 Sept 2026"},{"key":"3300_CR61","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s40120-025-00766-2","volume":"14","author":"P Odin","year":"2025","unstructured":"Odin P, T\u00e6rud C, Samuelsson J et al (2025) Levodopa intestinal gel infusion therapies in advanced Parkinson\u2019s disease: a Swedish study on real-world use and costs. Neurol Ther 14:1845\u20131860. https:\/\/doi.org\/10.1007\/s40120-025-00766-2","journal-title":"Neurol Ther"},{"key":"3300_CR62","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.prdoa.2025.100364","volume":"13","author":"S Ogata","year":"2025","unstructured":"Ogata S, Kimura K, Abe K, Urago Y, Hayashi N, Kunii M et al (2025) A case of Fr\u00e9goli syndrome following 24-hour levodopa-carbidopa intestinal gel infusion in a patient with Parkinson\u2019s disease undergoing STN-DBS. Clin Park Relat Disord 13:100364. https:\/\/doi.org\/10.1016\/j.prdoa.2025.100364","journal-title":"Clin Park Relat Disord"},{"key":"3300_CR63","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/archneur.62.8.noc40425","volume":"62","author":"MS Okun","year":"2005","unstructured":"Okun MS, Tagliati M, Pourfar M et al (2005) Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 62:1250\u20131255. https:\/\/doi.org\/10.1001\/archneur.62.8.noc40425","journal-title":"Arch Neurol"},{"key":"3300_CR64","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141\u2013149. https:\/\/doi.org\/10.1016\/S1474-4422(13)70293-X","journal-title":"Lancet Neurol"},{"key":"3300_CR65","doi-asserted-by":"publisher","first-page":"e16582","DOI":"10.1111\/ene.16582","volume":"32","author":"M \u00d6thman","year":"2025","unstructured":"\u00d6thman M, Bergquist F, Odin P et al (2025) Levodopa-entacapone-carbidopa intestinal gel: data from the Swedish national registry for Parkinson\u2019s disease. Eur J Neurol 32:e16582. https:\/\/doi.org\/10.1111\/ene.16582","journal-title":"Eur J Neurol"},{"key":"3300_CR66","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00702-024-02782-2","volume":"131","author":"O Phokaewvarangkul","year":"2024","unstructured":"Phokaewvarangkul O, Auffret M, Groppa S, Markovi\u0107 V, Petrovi\u0107 I, Bhidayasiri R (2024) What was first and what is next in selecting device-aided therapy in Parkinson\u2019s disease? Balancing evidence and experience. J Neural Transm (Vienna) 131:1307\u20131320. https:\/\/doi.org\/10.1007\/s00702-024-02782-2","journal-title":"J Neural Transm (Vienna)"},{"key":"3300_CR67","doi-asserted-by":"publisher","first-page":"e2078","DOI":"10.1212\/WNL.0000000000207858","volume":"101","author":"D P\u00fcrner","year":"2023","unstructured":"P\u00fcrner D, Hormozi M, Wei\u00df D et al (2023) Nationwide retrospective analysis of combinations of advanced therapies in patients with Parkinson disease. Neurology 101:e2078\u2013e2093. https:\/\/doi.org\/10.1212\/WNL.0000000000207858","journal-title":"Neurology"},{"key":"3300_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2022.867055","volume":"16","author":"V Ra\u010dki","year":"2022","unstructured":"Ra\u010dki V, Hero M, Ro\u017emari\u0107 G, Papi\u0107 E, Ragu\u017e M, Chudy D, Vuleti\u0107 V (2022) Cognitive impact of deep brain stimulation in Parkinson\u2019s disease patients: a systematic review. Front Hum Neurosci 16:867055. https:\/\/doi.org\/10.3389\/fnhum.2022.867055","journal-title":"Front Hum Neurosci"},{"key":"3300_CR69","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/WNF.0000000000000216","volume":"40","author":"I Regidor","year":"2017","unstructured":"Regidor I, Benita V, Del \u00c1lamo de Pedro M, Ley L, Martinez Castrillo JC (2017) Duodenal levodopa infusion for long-term deep brain stimulation-refractory symptoms in advanced Parkinson disease. Clin Neuropharmacol 40:103\u2013107. https:\/\/doi.org\/10.1097\/WNF.0000000000000216","journal-title":"Clin Neuropharmacol"},{"key":"3300_CR70","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.parkreldis.2014.01.012","volume":"20","author":"MG Rizzone","year":"2014","unstructured":"Rizzone MG, Fasano A, Daniele A et al (2014) Long-term outcome of subthalamic nucleus DBS in Parkinson\u2019s disease: from the advanced phase towards the late stage of the disease? Parkinsonism Relat Disord 20:376\u2013381. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.01.012","journal-title":"Parkinsonism Relat Disord"},{"key":"3300_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16535","volume":"32","author":"D Santos-Garc\u00eda","year":"2025","unstructured":"Santos-Garc\u00eda D, L\u00f3pez-Manzanares L, Muro I et al (2025) Effectiveness and safety of levodopa-entacapone-carbidopa infusion in Parkinson disease: a real-world data study. Eur J Neurol 32:e16535. https:\/\/doi.org\/10.1111\/ene.16535","journal-title":"Eur J Neurol"},{"key":"3300_CR72","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/brainsci16030343","volume":"16","author":"D Santos Garc\u00eda","year":"2026","unstructured":"Santos Garc\u00eda D, Legarda I, Gonz\u00e1lez Fern\u00e1ndez TM et al (2026) Outcome of people with Parkinson\u2019s disease treated with levodopa-entacapone-carbidopa intestinal gel who failed previous subcutaneous foslevodopa\/foscarbidopa. Brain Sci 16:343. https:\/\/doi.org\/10.3390\/brainsci16030343","journal-title":"Brain Sci"},{"key":"3300_CR73","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1055\/a-2238-1641","volume":"92","author":"N Schr\u00f6ter","year":"2024","unstructured":"Schr\u00f6ter N, Jost WH, Rijntjes M, Coenen V, Groppa S, Sajonz B (2024a) Synergien statt Rivalit\u00e4ten: die missverstandenen Rollen von kontinuierlicher intrajejunaler Levodopatherapie und Tiefer Hirnstimulation in der Behandlung des Morbus Parkinson, eine Expertenmeinung. Fortschr Neurol Psychiatr 92:502\u2013508. https:\/\/doi.org\/10.1055\/a-2238-1641","journal-title":"Fortschr Neurol Psychiatr"},{"key":"3300_CR74","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00702-024-02773-3","volume":"131","author":"N Schr\u00f6ter","year":"2024","unstructured":"Schr\u00f6ter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S (2024b) Advanced therapies in Parkinson\u2019s disease: an individualized approach to their indication. J Neural Transm 131:1285\u20131293. https:\/\/doi.org\/10.1007\/s00702-024-02773-3","journal-title":"J Neural Transm"},{"key":"3300_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75052-2","volume":"10","author":"M Senek","year":"2020","unstructured":"Senek M, Nyholm D, Nielsen EI (2020) Population pharmacokinetics of levodopa gel infusion in Parkinson\u2019s disease: effects of entacapone infusion and genetic polymorphism. Sci Rep 10:18057. https:\/\/doi.org\/10.1038\/s41598-020-75052-2","journal-title":"Sci Rep"},{"key":"3300_CR76","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00415-019-09184-5","volume":"266","author":"\u00c1 Sesar","year":"2019","unstructured":"Sesar \u00c1, Fern\u00e1ndez-Pajar\u00edn G, Ares B et al (2019) Continuous subcutaneous apomorphine in advanced Parkinson\u2019s disease patients treated with deep brain stimulation. J Neurol 266:659\u2013666. https:\/\/doi.org\/10.1007\/s00415-019-09184-5","journal-title":"J Neurol"},{"key":"3300_CR77","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099\u20131109. https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"key":"3300_CR78","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40734-021-00091-4","volume":"7","author":"F Spagnolo","year":"2021","unstructured":"Spagnolo F, Romeo F, Proto P et al (2021) Continuous subcutaneous apomorphine infusion allowing awake deep brain stimulation in a Parkinson\u2019s disease patient. J Clin Mov Disord 7:9. https:\/\/doi.org\/10.1186\/s40734-021-00091-4","journal-title":"J Clin Mov Disord"},{"key":"3300_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1547557","volume":"16","author":"I Straka","year":"2025","unstructured":"Straka I, Andre Z, Kosutzka Z et al (2025) Complications associated with intestinal infusion therapies in patients with Parkinson\u2019s disease: a single-center retrospective study and 15-year experience. Front Neurol 16:1547557. https:\/\/doi.org\/10.3389\/fneur.2025.1547557","journal-title":"Front Neurol"},{"key":"3300_CR80","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1097\/MJT.0000000000001707","volume":"31","author":"JA Sz\u00e1sz","year":"2024","unstructured":"Sz\u00e1sz JA, Dulamea AO, Constantin VA et al (2024) Levodopa-carbidopa-entacapone intestinal gel in advanced Parkinson disease: a multicenter real-life experience. Am J Ther 31:e209\u2013e218. https:\/\/doi.org\/10.1097\/MJT.0000000000001707","journal-title":"Am J Ther"},{"key":"3300_CR81","doi-asserted-by":"publisher","first-page":"300","DOI":"10.5603\/pjnns.107157","volume":"60","author":"S Szlufik","year":"2026","unstructured":"Szlufik S, Jaros K, Milanowski \u0141, Mandat T, Koziorowski D (2026) Adding continuous infusion therapies after bilateral subthalamic deep brain stimulation in advanced Parkinson\u2019s disease: clinical outcomes and quality of life assessment in a case series. Neurol Neurochir Pol 60:300\u2013309. https:\/\/doi.org\/10.5603\/pjnns.107157","journal-title":"Neurol Neurochir Pol"},{"key":"3300_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060547","volume":"11","author":"D van Poppelen","year":"2021","unstructured":"van Poppelen D, Tromp ANM, de Bie RMA, Dijk JM (2021) Combined and sequential treatment with deep brain stimulation and continuous intrajejunal levodopa infusion for Parkinson\u2019s disease. J Pers Med 11:547. https:\/\/doi.org\/10.3390\/jpm11060547","journal-title":"J Pers Med"},{"key":"3300_CR83","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/jnnp-2013-306336","volume":"85","author":"S Vercruysse","year":"2014","unstructured":"Vercruysse S, Vandenberghe W, M\u00fcnks L et al (2014) Effects of deep brain stimulation of the subthalamic nucleus on freezing of gait in Parkinson\u2019s disease: a prospective controlled study. J Neurol Neurosurg Psychiatry 85:871\u2013877. https:\/\/doi.org\/10.1136\/jnnp-2013-306336","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3300_CR84","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/mdc3.13926","volume":"11","author":"V Viljaharju","year":"2024","unstructured":"Viljaharju V, Mertsalmi T, Pauls KAM et al (2024) Levodopa-entacapone-carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease: a single-center study of 30 patients. Mov Disord Clin Pract 11:159\u2013165. https:\/\/doi.org\/10.1002\/mdc3.13926","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR85","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000548570","volume":"88","author":"V Viljaharju","year":"2025","unstructured":"Viljaharju V, Mertsalmi T, Pauls KAM et al (2025) Living alone is associated with discontinuation of levodopa-entacapone-carbidopa intestinal gel treatment in advanced Parkinson\u2019s disease. Eur Neurol 88:159\u2013166. https:\/\/doi.org\/10.1159\/000548570","journal-title":"Eur Neurol"},{"key":"3300_CR86","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00702-025-03033-8","volume":"133","author":"T Warnecke","year":"2026","unstructured":"Warnecke T, Odin P, Garc\u00eda-Ramos R et al (2026) Effects of levodopa-entacapone-carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson\u2019s disease: interim analysis of the ELEGANCE study. J Neural Transm 133:779\u2013789. https:\/\/doi.org\/10.1007\/s00702-025-03033-8","journal-title":"J Neural Transm"},{"key":"3300_CR87","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/mdc3.70046","volume":"12","author":"D Weiss","year":"2025","unstructured":"Weiss D, Jost WH, Sz\u00e1sz JA et al (2025) Levodopa-entacapone-carbidopa intrajejunal infusion in advanced Parkinson\u2019s disease: interim analysis of the ELEGANCE study. Mov Disord Clin Pract 12:1075\u20131085. https:\/\/doi.org\/10.1002\/mdc3.70046","journal-title":"Mov Disord Clin Pract"},{"key":"3300_CR88","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1212\/WNL.0000000000001184","volume":"84","author":"T Xie","year":"2015","unstructured":"Xie T, Vigil J, MacCracken E et al (2015) Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology 84:415\u2013420. https:\/\/doi.org\/10.1212\/WNL.0000000000001184","journal-title":"Neurology"},{"key":"3300_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-017-0083-7","volume":"6","author":"T Xie","year":"2017","unstructured":"Xie T, Padmanaban M, Bloom L et al (2017) Effect of low versus high frequency stimulation on freezing of gait and other axial symptoms in Parkinson patients with bilateral STN DBS: a mini-review. Transl Neurodegener 6:13. https:\/\/doi.org\/10.1186\/s40035-017-0083-7","journal-title":"Transl Neurodegener"},{"key":"3300_CR90","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/jnnp-2018-318060","volume":"89","author":"T Xie","year":"2018","unstructured":"Xie T, Bloom L, Padmanaban M et al (2018) Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry 89:989\u2013994. https:\/\/doi.org\/10.1136\/jnnp-2018-318060","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03300-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03300-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03300-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:12:20Z","timestamp":1790608340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03300-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":90,"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03300-2","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"30 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This review contains no studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}